|
GBAS expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6278089987054E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
1.313210E-01 |
| Normal-vs-Stage3 |
4.29434265925011E-13 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
1.676090E-03 |
| Stage1-vs-Stage3 |
7.257600E-01 |
| Stage1-vs-Stage4 |
8.754400E-04 |
| Stage2-vs-Stage3 |
1.964420E-03 |
| Stage2-vs-Stage4 |
3.89200000000534E-05 |
| Stage3-vs-Stage4 |
5.932200E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.16799999672068E-08 |
| Normal-vs-Asian |
2.72049049954148E-12 |
| Caucasian-vs-AfricanAmerican |
8.419200E-01 |
| Caucasian-vs-Asian |
8.225000E-01 |
| AfricanAmerican-vs-Asian |
9.451200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.28785870856518E-14 |
| Male-vs-Female |
3.449200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
6.59472476627343E-14 |
| Normal-vs-Age(61-80Yrs) |
9.20580001118054E-09 |
| Normal-vs-Age(81-100Yrs) |
1.64681E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.169600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.260400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.752200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.007000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.603600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.014200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.366100E-04 |
| Classical-VS-Follicular |
1.06149999901106E-08 |
| Classical-VS-Other |
6.300400E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
1.59339208494202E-12 |
| Tall-VS-Other |
1.426840E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
1.270780E-01 |
| Follicular-VS-Normal |
2.653600E-02 |
| Other-VS-Normal |
5.152700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.07690547987727E-11 |
| Normal-vs-N1 |
1.62436730732907E-12 |
| N0-vs-N1 |
1.94229999972428E-07 |
|
|
